ROBERT G GISH
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Hepatology
- Where
- FOLSOM, CA
- NPI
- 1548281322
- Received
- $1,910,177 in 1,565 records, 2019 to 2025 ($1,888,577 general, $21,600 research)
- As principal investigator
- $350 of research payments to others in 1 record
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 300 | $353,789 |
| 2025 | Research payment | 5 | $10,200 |
| 2024 | General payment | 271 | $415,107 |
| 2024 | Research payment | 3 | $6,900 |
| 2023 | General payment | 286 | $310,381 |
| 2023 | Research payment | 6 | $4,500 |
| 2022 | General payment | 206 | $206,343 |
| 2021 | General payment | 101 | $127,972 |
| 2020 | General payment | 118 | $168,217 |
| 2019 | General payment | 269 | $306,766 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 217 | $875,177 |
| Consulting Fee | 169 | $469,585 |
| Travel and Lodging | 557 | $218,998 |
| Compensation for serving as faculty or as a speaker for a medical education program | 48 | $209,662 |
| Honoraria | 26 | $46,517 |
| Food and Beverage | 516 | $34,138 |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing | 11 | $31,400 |
| Research payment | 14 | $21,600 |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing educat | 1 | $3,000 |
| Education | 6 | $98 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-19 | Mirum Pharmaceuticals, Inc. | $385 | Consulting Fee | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-12-17 | Ipsen Biopharmaceuticals, Inc | $2,754 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Bylvay Drug, Gastroenterology | 2025 | |
| 2025-12-16 | Madrigal Pharmaceuticals | $3,878 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-12-16 | Madrigal Pharmaceuticals | $126 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-12-16 | Madrigal Pharmaceuticals | $46 | Travel and Lodging | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-12-15 | Madrigal Pharmaceuticals | $5,993 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-12-15 | Madrigal Pharmaceuticals | $325 | Travel and Lodging | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-12-15 | Madrigal Pharmaceuticals | $211 | Travel and Lodging | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-12-15 | Madrigal Pharmaceuticals | $149 | Travel and Lodging | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-12-15 | Madrigal Pharmaceuticals | $100 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-12-15 | Madrigal Pharmaceuticals | $35 | Food and Beverage | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-12-13 | Madrigal Pharmaceuticals | $82 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-12-13 | Madrigal Pharmaceuticals | $63 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-12-13 | Mirum Pharmaceuticals, Inc. | $31 | Food and Beverage | In-kind items and services | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-12-12 | Takeda Pharmaceuticals U.S.A., Inc. | $2,700 | Research payment | Cash or cash equivalent | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSI | 2025 | |
| 2025-12-12 | GlaxoSmithKline, LLC. | $1,200 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-12-11 | Gilead Sciences, Inc. | $3,790 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Livdelzi Drug, INFLAM | 2025 | |
| 2025-12-10 | Ipsen Biopharmaceuticals, Inc | $1,377 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Bylvay Drug, Gastroenterology | 2025 | |
| 2025-12-09 | Madrigal Pharmaceuticals | $5,993 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-12-09 | Gilead Sciences, Inc. | $124 | Travel and Lodging | In-kind items and services | Vemlidy Drug, HBV | 2025 | |
| 2025-12-09 | Madrigal Pharmaceuticals | $17 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-12-07 | Madrigal Pharmaceuticals | $136 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-12-07 | Madrigal Pharmaceuticals | $10 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-12-05 | Gilead Sciences, Inc. | $1,242 | Travel and Lodging | In-kind items and services | Livdelzi Drug, INFLAM | 2025 | |
| 2025-12-04 | Gilead Sciences, Inc. | $6,440 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-12-04 | Gilead Sciences, Inc. | $25 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-12-03 | Gilead Sciences, Inc. | $389 | Travel and Lodging | In-kind items and services | Livdelzi Drug, INFLAM | 2025 | |
| 2025-12-02 | Gilead Sciences, Inc. | $418 | Travel and Lodging | In-kind items and services | Livdelzi Drug, INFLAM | 2025 | |
| 2025-12-02 | Gilead Sciences, Inc. | $133 | Food and Beverage | In-kind items and services | Livdelzi Drug, INFLAM | 2025 | |
| 2025-12-02 | Gilead Sciences, Inc. | $20 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-24 | Gilead Sciences, Inc. | $3,790 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Vemlidy Drug, HBV | 2025 | |
| 2025-11-24 | Madrigal Pharmaceuticals | $42 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-11-24 | Gilead Sciences, Inc. | $19 | Education | In-kind items and services | 2025 | ||
| 2025-11-24 | Mirum Pharmaceuticals, Inc. | $11 | Food and Beverage | In-kind items and services | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-11-21 | Takeda Pharmaceuticals U.S.A., Inc. | $28 | Food and Beverage | In-kind items and services | ENTYVIO Biological, INTERNAL MEDICINE | 2025 | |
| 2025-11-20 | Madrigal Pharmaceuticals | $5,993 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-11-20 | Madrigal Pharmaceuticals | $388 | Travel and Lodging | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-11-20 | Madrigal Pharmaceuticals | $144 | Travel and Lodging | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-11-20 | Madrigal Pharmaceuticals | $128 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-11-19 | ORPHALAN INC | $3,000 | Honoraria | Cash or cash equivalent | CUVRIOR Drug, Hepatology | 2025 | |
| 2025-11-18 | Gilead Sciences, Inc. | $143 | Food and Beverage | In-kind items and services | Vemlidy Drug, HBV | 2025 | |
| 2025-11-13 | Novo Nordisk Inc | $18 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-11-12 | Madrigal Pharmaceuticals | $5,993 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-11-12 | Madrigal Pharmaceuticals | $301 | Travel and Lodging | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-11-12 | Madrigal Pharmaceuticals | $276 | Travel and Lodging | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-11-12 | Madrigal Pharmaceuticals | $207 | Travel and Lodging | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-11-12 | Mallinckrodt Hospital Products Inc. | $164 | Travel and Lodging | Cash or cash equivalent | TERLIVAZ Drug, CRITICAL CARE | 2025 | |
| 2025-11-12 | Madrigal Pharmaceuticals | $144 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-11-12 | Mallinckrodt Hospital Products Inc. | $33 | Food and Beverage | Cash or cash equivalent | TERLIVAZ Drug, CRITICAL CARE | 2025 | |
| 2025-11-11 | Ipsen Biopharmaceuticals, Inc | $4,800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-11-11 | Ipsen Biopharmaceuticals, Inc | $399 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-11-09 | Mirum Pharmaceuticals, Inc. | $3,080 | Consulting Fee | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-11-07 | GlaxoSmithKline, LLC. | $800 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-11-07 | Gilead Sciences, Inc. | $137 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-29 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | CREON Drug, ENDOCRINOLOGY | 2025 | |
| 2025-10-28 | Mallinckrodt Hospital Products Inc. | $6,900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TERLIVAZ Drug, CRITICAL CARE | 2025 | |
| 2025-10-28 | Mirum Pharmaceuticals, Inc. | $3,080 | Consulting Fee | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-10-28 | Mirum Pharmaceuticals, Inc. | $1,540 | Consulting Fee | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-10-28 | Mirum Pharmaceuticals, Inc. | $638 | Travel and Lodging | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-10-28 | GlaxoSmithKline, LLC. | $555 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-10-28 | GlaxoSmithKline, LLC. | $431 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-10-28 | Mirum Pharmaceuticals, Inc. | $382 | Travel and Lodging | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-10-28 | Mirum Pharmaceuticals, Inc. | $152 | Travel and Lodging | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-10-28 | Mirum Pharmaceuticals, Inc. | $138 | Travel and Lodging | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-10-28 | Mirum Pharmaceuticals, Inc. | $130 | Travel and Lodging | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-10-28 | Mirum Pharmaceuticals, Inc. | $128 | Travel and Lodging | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-10-28 | Mirum Pharmaceuticals, Inc. | $125 | Food and Beverage | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-10-28 | Mirum Pharmaceuticals, Inc. | $64 | Travel and Lodging | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-10-28 | Mirum Pharmaceuticals, Inc. | $27 | Travel and Lodging | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-10-28 | Mirum Pharmaceuticals, Inc. | $26 | Food and Beverage | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-10-24 | GlaxoSmithKline, LLC. | $8,000 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-10-24 | Gilead Sciences, Inc. | $2,040 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-10-24 | Mallinckrodt Hospital Products Inc. | $308 | Travel and Lodging | In-kind items and services | TERLIVAZ Drug, CRITICAL CARE | 2025 | |
| 2025-10-24 | Gilead Sciences, Inc. | $68 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-24 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | CREON Drug, ENDOCRINOLOGY | 2025 | |
| 2025-10-24 | Gilead Sciences, Inc. | $12 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-23 | Mallinckrodt Hospital Products Inc. | $613 | Travel and Lodging | In-kind items and services | TERLIVAZ Drug, CRITICAL CARE | 2025 | |
| 2025-10-23 | Mallinckrodt Hospital Products Inc. | $348 | Travel and Lodging | In-kind items and services | TERLIVAZ Drug, CRITICAL CARE | 2025 | |
| 2025-10-23 | Mallinckrodt Hospital Products Inc. | $146 | Food and Beverage | In-kind items and services | TERLIVAZ Drug, CRITICAL CARE | 2025 | |
| 2025-10-16 | ABBVIE INC. | $30 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-10-15 | Madrigal Pharmaceuticals | $5,993 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-10-15 | Madrigal Pharmaceuticals | $524 | Travel and Lodging | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-10-15 | Madrigal Pharmaceuticals | $451 | Travel and Lodging | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-10-15 | Madrigal Pharmaceuticals | $219 | Travel and Lodging | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-10-15 | Madrigal Pharmaceuticals | $74 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-10-10 | Gilead Sciences, Inc. | $60 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-10 | Gilead Sciences, Inc. | $59 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-10 | Gilead Sciences, Inc. | $26 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-10 | Gilead Sciences, Inc. | $17 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-10 | Gilead Sciences, Inc. | $17 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-02 | Neurocrine BioSciences, Inc. | $2,750 | Consulting Fee | Cash or cash equivalent | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-10-02 | Ardelyx, Inc. | $30 | Food and Beverage | In-kind items and services | IBSRELA Drug, GASTROENTEROLOGY | 2025 | |
| 2025-09-25 | ORPHALAN INC | $53 | Food and Beverage | In-kind items and services | CUVRIOR Drug, Hepatology | 2025 | |
| 2025-09-23 | Ipsen Biopharmaceuticals, Inc | $1,377 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | IQIRVO Drug, Rare Disease | 2025 | |
| 2025-09-22 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2025 | |
| 2025-09-20 | Ipsen Biopharmaceuticals, Inc | $2,754 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | IQIRVO Drug, Rare Disease | 2025 | |
| 2025-09-20 | Ipsen Biopharmaceuticals, Inc | $507 | Travel and Lodging | In-kind items and services | IQIRVO Drug, Rare Disease | 2025 | |
| 2025-09-20 | Ipsen Biopharmaceuticals, Inc | $170 | Travel and Lodging | In-kind items and services | IQIRVO Drug, Rare Disease | 2025 | |
| 2025-09-20 | Ipsen Biopharmaceuticals, Inc | $71 | Food and Beverage | In-kind items and services | IQIRVO Drug, Rare Disease | 2025 | |
| 2025-09-19 | Ipsen Biopharmaceuticals, Inc | $7,803 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | IQIRVO Drug, Rare Disease | 2025 | |
| 2025-09-19 | Ipsen Biopharmaceuticals, Inc | $1,238 | Travel and Lodging | In-kind items and services | IQIRVO Drug, Rare Disease | 2025 | |
| 2025-09-19 | Ipsen Biopharmaceuticals, Inc | $1,151 | Travel and Lodging | In-kind items and services | IQIRVO Drug, Rare Disease | 2025 | |
| 2025-09-19 | Ipsen Biopharmaceuticals, Inc | $200 | Food and Beverage | In-kind items and services | IQIRVO Drug, Rare Disease | 2025 | |
| 2025-09-11 | Ipsen Biopharmaceuticals, Inc | $5,967 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | IQIRVO Drug, Rare Disease | 2025 | |
| 2025-09-11 | Ipsen Biopharmaceuticals, Inc | $193 | Travel and Lodging | In-kind items and services | IQIRVO Drug, Rare Disease | 2025 | |
| 2025-09-11 | Ipsen Biopharmaceuticals, Inc | $121 | Food and Beverage | In-kind items and services | IQIRVO Drug, Rare Disease | 2025 | |
| 2025-09-11 | Ipsen Biopharmaceuticals, Inc | $61 | Travel and Lodging | In-kind items and services | IQIRVO Drug, Rare Disease | 2025 | |
| 2025-09-10 | Ipsen Biopharmaceuticals, Inc | $5,967 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | IQIRVO Drug, Rare Disease | 2025 | |
| 2025-09-10 | Ipsen Biopharmaceuticals, Inc | $1,214 | Travel and Lodging | In-kind items and services | IQIRVO Drug, Rare Disease | 2025 | |
| 2025-09-10 | Mirum Pharmaceuticals, Inc. | $1,155 | Consulting Fee | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-09-10 | Ipsen Biopharmaceuticals, Inc | $238 | Travel and Lodging | In-kind items and services | IQIRVO Drug, Rare Disease | 2025 | |
| 2025-09-10 | Ipsen Biopharmaceuticals, Inc | $128 | Food and Beverage | In-kind items and services | IQIRVO Drug, Rare Disease | 2025 | |
| 2025-09-09 | Madrigal Pharmaceuticals | $5,993 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-09-09 | Madrigal Pharmaceuticals | $2,468 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-09-09 | Madrigal Pharmaceuticals | $1,851 | Travel and Lodging | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-09-09 | Madrigal Pharmaceuticals | $257 | Travel and Lodging | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-09-09 | Madrigal Pharmaceuticals | $238 | Travel and Lodging | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-09-09 | Madrigal Pharmaceuticals | $121 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-09-09 | Madrigal Pharmaceuticals | $8 | Food and Beverage | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-09-04 | Gilead Sciences, Inc. | $25 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-03 | Mirum Pharmaceuticals, Inc. | $3,900 | Consulting Fee | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-09-03 | Mirum Pharmaceuticals, Inc. | $1,300 | Consulting Fee | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-09-03 | Mirum Pharmaceuticals, Inc. | $598 | Travel and Lodging | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-09-03 | Mirum Pharmaceuticals, Inc. | $128 | Travel and Lodging | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-09-03 | Mirum Pharmaceuticals, Inc. | $122 | Food and Beverage | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-09-03 | Mirum Pharmaceuticals, Inc. | $114 | Travel and Lodging | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-09-03 | Mirum Pharmaceuticals, Inc. | $68 | Travel and Lodging | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-09-03 | Mirum Pharmaceuticals, Inc. | $54 | Travel and Lodging | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-09-03 | Mirum Pharmaceuticals, Inc. | $35 | Travel and Lodging | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-09-03 | Mirum Pharmaceuticals, Inc. | $18 | Food and Beverage | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-09-02 | GlaxoSmithKline, LLC. | $4,000 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-09-02 | Intercept Pharmaceuticals, Inc. | $1,995 | Consulting Fee | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | 2025 | |
| 2025-09-02 | Ipsen Biopharmaceuticals, Inc | $24 | Food and Beverage | In-kind items and services | IQIRVO Drug, Rare Disease | 2025 | |
| 2025-08-30 | Eton Pharmaceuticals, Inc. | $21 | Food and Beverage | Cash or cash equivalent | GALZIN Drug, Metabolics | 2025 | |
| 2025-08-27 | Mirum Pharmaceuticals, Inc. | $1,925 | Consulting Fee | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-08-27 | Mirum Pharmaceuticals, Inc. | $137 | Food and Beverage | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-08-25 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $24 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-08-21 | Madrigal Pharmaceuticals | $5,993 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-08-21 | Madrigal Pharmaceuticals | $370 | Travel and Lodging | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-08-21 | Madrigal Pharmaceuticals | $266 | Travel and Lodging | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-08-21 | Madrigal Pharmaceuticals | $148 | Travel and Lodging | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-08-21 | Madrigal Pharmaceuticals | $111 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-08-21 | Madrigal Pharmaceuticals | $48 | Food and Beverage | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-08-20 | Madrigal Pharmaceuticals | $59 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-08-18 | Mirum Pharmaceuticals, Inc. | $21 | Food and Beverage | In-kind items and services | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-08-08 | Lilly USA, LLC | $19 | Food and Beverage | In-kind items and services | OMVOH Drug, Immunology | 2025 | |
| 2025-08-06 | Mirum Pharmaceuticals, Inc. | $3,080 | Consulting Fee | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-08-06 | Mirum Pharmaceuticals, Inc. | $1,540 | Consulting Fee | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-08-06 | Mirum Pharmaceuticals, Inc. | $238 | Travel and Lodging | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-08-06 | Mirum Pharmaceuticals, Inc. | $218 | Travel and Lodging | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-08-06 | Mirum Pharmaceuticals, Inc. | $127 | Food and Beverage | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-08-06 | Mirum Pharmaceuticals, Inc. | $51 | Travel and Lodging | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-08-06 | Mirum Pharmaceuticals, Inc. | $30 | Travel and Lodging | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-08-06 | Mirum Pharmaceuticals, Inc. | $24 | Travel and Lodging | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-08-06 | Mirum Pharmaceuticals, Inc. | $20 | Travel and Lodging | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-08-06 | Mirum Pharmaceuticals, Inc. | $19 | Food and Beverage | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-08-05 | Gilead Sciences, Inc. | $88 | Travel and Lodging | In-kind items and services | Livdelzi Drug, INFLAM | 2025 | |
| 2025-08-05 | Gilead Sciences, Inc. | $34 | Food and Beverage | Cash or cash equivalent | Livdelzi Drug, INFLAM | 2025 | |
| 2025-08-04 | GlaxoSmithKline, LLC. | $3,200 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-07-30 | Mirum Pharmaceuticals, Inc. | $5,775 | Consulting Fee | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-07-30 | Mirum Pharmaceuticals, Inc. | $3,080 | Consulting Fee | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-07-30 | Intercept Pharmaceuticals, Inc. | $2,170 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | 2025 | |
| 2025-07-30 | Mirum Pharmaceuticals, Inc. | $782 | Travel and Lodging | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-07-30 | Mirum Pharmaceuticals, Inc. | $713 | Travel and Lodging | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-07-30 | Mirum Pharmaceuticals, Inc. | $127 | Food and Beverage | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-07-30 | Mirum Pharmaceuticals, Inc. | $116 | Food and Beverage | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-07-30 | Mirum Pharmaceuticals, Inc. | $73 | Travel and Lodging | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-07-30 | Mirum Pharmaceuticals, Inc. | $67 | Food and Beverage | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-07-30 | Mirum Pharmaceuticals, Inc. | $56 | Travel and Lodging | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-07-30 | Mirum Pharmaceuticals, Inc. | $40 | Travel and Lodging | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-07-30 | Mirum Pharmaceuticals, Inc. | $31 | Food and Beverage | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-07-30 | Mirum Pharmaceuticals, Inc. | $27 | Travel and Lodging | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-07-30 | Mirum Pharmaceuticals, Inc. | $27 | Food and Beverage | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-07-30 | Mirum Pharmaceuticals, Inc. | $25 | Food and Beverage | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-07-30 | Mirum Pharmaceuticals, Inc. | $21 | Travel and Lodging | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-07-30 | Mirum Pharmaceuticals, Inc. | $17 | Food and Beverage | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-07-30 | Mirum Pharmaceuticals, Inc. | $15 | Food and Beverage | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-07-24 | Gilead Sciences, Inc. | $6,440 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Livdelzi Drug, INFLAM | 2025 | |
| 2025-07-22 | Ipsen Biopharmaceuticals, Inc | $2,754 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Bylvay Drug, Gastroenterology | 2025 | |
| 2025-07-22 | ABBVIE INC. | $10 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2025 | |
| 2025-07-19 | Madrigal Pharmaceuticals | $94 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-07-19 | Madrigal Pharmaceuticals | $70 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-07-19 | Madrigal Pharmaceuticals | $57 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-07-19 | Madrigal Pharmaceuticals | $38 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-07-18 | Madrigal Pharmaceuticals | $5,287 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-07-18 | Madrigal Pharmaceuticals | $495 | Travel and Lodging | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-07-18 | Madrigal Pharmaceuticals | $244 | Travel and Lodging | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-07-18 | Madrigal Pharmaceuticals | $196 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-07-18 | Madrigal Pharmaceuticals | $159 | Travel and Lodging | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-07-18 | Madrigal Pharmaceuticals | $90 | Travel and Lodging | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-07-16 | GlaxoSmithKline, LLC. | $30 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-15 | Ipsen Biopharmaceuticals, Inc | $1,377 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | IQIRVO Drug, Rare Disease | 2025 | |
| 2025-07-15 | GlaxoSmithKline, LLC. | $1,200 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-07-15 | ABBVIE INC. | $37 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2025 | |
| 2025-07-14 | Gilead Sciences, Inc. | $1,178 | Travel and Lodging | In-kind items and services | Livdelzi Drug, INFLAM | 2025 | |
| 2025-07-10 | Gilead Sciences, Inc. | $193 | Travel and Lodging | In-kind items and services | Livdelzi Drug, INFLAM | 2025 | |
| 2025-07-10 | Gilead Sciences, Inc. | $119 | Food and Beverage | In-kind items and services | Livdelzi Drug, INFLAM | 2025 | |
| 2025-07-08 | Madrigal Pharmaceuticals | $28 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-07-07 | Mirum Pharmaceuticals, Inc. | $1,925 | Consulting Fee | Cash or cash equivalent | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-06-25 | Madrigal Pharmaceuticals | $18 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 |
The latest 200 records of 1,565.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2021-06-09 | Eiger BioPharmaceuticals, Inc. | ROBERT G GISH CONSULTANTS LLC | $350 | EXD-001 | 2021 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Folsom, CA, county Sacramento County, CA, state California; placed by its city name.
| Measure | Place (city or town) Folsom, CA | County Sacramento County, CA | State California |
|---|---|---|---|
| Population B01003 | 83,916 | 1,594,006 | 39,287,377 |
| Population, 2020 census P1 | 80,454 | 1,585,055 | 39,538,223 |
| Median age B01002 | 41.0 | 37.5 | 37.9 |
| Under 18 B01001 | 22.7% | 22.9% | 22.0% |
| 65 and over B01001 | 14.8% | 15.3% | 15.7% |
| Households B11001 | 29,963 | 571,057 | 13,548,091 |
| Foreign born B05002 | 20.2% | 22.3% | 27.0% |
| Median household income B19013 | $139,804 | $92,175 | $99,122 |
| Median family income B19113 | $176,762 | $107,555 | $113,346 |
| Per capita income B19301 | $62,962 | $43,324 | $49,513 |
| Poverty rate B17001 | 5.3% | 12.5% | 12.0% |
| Unemployment rate B23025 | 6.3% | 6.7% | 6.6% |
| Civilian labor force B23025 | 42,016 | 805,946 | 20,068,466 |
| Mean commute (minutes) B08013 | 26.6 | 27.3 | 28.7 |
| Bachelor's degree or higher B15003 | 54.9% | 34.1% | 37.1% |
| Housing units B25001 | 30,868 | 598,385 | 14,644,735 |
| Owner-occupied B25003 | 69.7% | 59.0% | 55.9% |
| Renters B25003 | 30.3% | 41.0% | 44.1% |
| Median home value B25077 | $755,200 | $534,200 | $734,700 |
| Median gross rent B25064 | $2,352 | $1,790 | $2,036 |
| White, not Hispanic B03002 | 54.2% | 40.6% | 33.8% |
| Black B03002 | 5.3% | 9.0% | 5.2% |
| Hispanic or Latino B03002 | 13.9% | 24.2% | 40.2% |
| Asian B03002 | 19.9% | 17.6% | 15.3% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Folsom, CA.
Comments